Cool Weather Hits AutoZone Hard: Q3 Sales Miss Expectations, Shares Drop
AutoZone profit beat estimates but sales missed; cool weather slowed demand and shares fell about 10%.
Already have an account? Sign in.
AutoZone profit beat estimates but sales missed; cool weather slowed demand and shares fell about 10%.
Truist calls Vertex’s Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for Maze.
Deal adds oral and brain-targeted FA treatments to Lexeo’s pipeline. LX2006 gene therapy stays top priority, with pivotal data due in late 2027.
FDA lifted the clinical hold on Filana’s simufilam, clearing a Phase 2a study in TSC-related epilepsy. Lucid Capital keeps a Buy rating and $8 target.